SAB BIO Q3 2026 Earnings Call - SAB BIOTHERAPEUTICS INC

Explicit Guidance:

• Reaffirmed timeline to complete enrollment of the "SAFEGUARD" clinical trial in Q4 2026.
• Expected release of top-line data for the SAFEGUARD study in the second half of 2027.
• Projected cash runway sufficient to fund operations through 2028 based on an ending balance of $205 million (as of Sept 30, 2026).
• Expenditure for the "PRIZE" investigator-led study is fully incorporated into the existing budgeted burn rate; no additional financial impact on guidance is expected.

Business-Segment Outlook:

• Clinical Progress: SAFEGUARD (Phase 2b) has closed adult and adolescent cohorts; step-down to children ages 5–11 approved in September to accelerate enrollment. PRIZE (Phase 3) initiated dosing first patients in Q3 2026 across 7 sites (US, Europe, UK).
• Pipeline Expansion: Successful PRIZE enrollment and positive data could support a future label expansion for SAB-142 to treat patients up to two years from a stage 3 diagnosis.
• Long-term Strategy: Infrastructure and capabilities are being built to support commercial readiness and long-term disease modification via redosing capabilities.

Market and Competitive Outlook:

• Competitive Landscape: Anticipates a favorable environment driven by the recent FDA approval of T-field, which is expected to establish physician/patient patterns for early treatment to preserve pancreatic function, potentially expanding the addressable market.
• Differentiation: Positions SAB-142 as having a superior profile to competitors due to fully human antibody status, enabling low immunogenicity and the potential for safe long-term redosing over the patient's lifetime.
• Demand Trends: Reports "tremendous interest" and "pent-up demand" from physicians and patients excluded from current therapies due to narrow enrollment windows (e.g., T-field's 8-week limit vs. SAB-142's 100-day limit in SAFEGUARD).

Macro / Industry Outlook:

• Regulatory: FDA granted Fast-Track designation for new-onset stage 3 type 1 diabetes, anticipated to expedite review via more frequent meetings, written communications, and potential eligibility for Priority Review and Rolling BLA submission.
• Industry Dynamics: The T1D community is increasingly focused on disease-modifying therapies; success of SAB-142 could shift treatment paradigms from "gun to the head" urgency to broader access based on C-peptide status rather than strict time-from-diagnosis constraints.

Strategic Initiatives:

• Clinical Execution: Accelerating SAFEGUARD enrollment by adding pediatric cohorts; initiating PRIZE study to test efficacy in patients up to two years post-diagnosis.
• Capacity & Operations: Expanding clinical trial infrastructure to support potential global commercialization post-approval.
• Partnerships: Continuing collaboration with Breakthrough T1D (funding/support) and academic investigators (e.g., Dr. Michael Haller, Dr. Chantal Matthew, Dr. Timothy Tree) for the PRIZE study.

Risks and Headwinds to Outlook:

• Clinical Uncertainty: FDA approval is not guaranteed despite Fast-Track designation; final top-line data must demonstrate statistical significance on C-peptide preservation and glycemic control.
• Regulatory Scope: Fast-Track status does not alter FDA standards for approval; label expansion to two years post-diagnosis is contingent on positive PRIZE data.
• Data Limitations: Historical Phase I "super responder" data (120-day follow-up) has concluded; durability of response without redosing remains unmeasured beyond that period.

Management Tone on the Future:

• Confidence: Management expresses strong conviction regarding the clinical trajectory, citing "exemplary" performance of the clinical team and consistent safety profiles across age groups.
• Sentiment: Optimistic about the market opportunity created by T-field's approval, viewing it as a catalyst for SAB-142 adoption. Tone is confident but measured, explicitly stating that Fast-Track designation is a procedural benefit rather than a guarantee of approval.
• Hedges: Acknowledges that actual results may differ materially due to factors outlined in SEC filings; avoids specific financial metrics beyond cash runway.

Miscellaneous:

• Enrollment Specifics: SAFEGUARD adult/adolescent cohorts are fully enrolled; PRIZE will utilize a 1/3 split across adult, adolescent, and pediatric populations.
• Safety Profile: Independent Data Monitoring Committee (DMC) confirmed no new safety signals in pediatric cohorts, allowing for the step-down enrollment.
• Financial Update: Q3 2026 R&D expenses rose to $18.1M (vs. $9M in Q3 2025) driven by clinical trial costs and headcount; G&A rose to $7.8M (vs. $3.7M).